Skip to main content

Day: April 27, 2021

ES Bancshares, Inc. Reports March 31, 2021 Quarterly Earnings of $1.0 Million, or $0.15 per Common Share, as Compared to a Loss of $95 Thousand, or $0.01 per Common Share for the Quarter Ended March 31, 2020

NET INTERST MARGIN IMPROVES TO 3.48% FOR THE QUARTER ENDED MARCH 31, 2021 COMPARED TO 3.02% FOR THE COMPARABLE 2020 QUARTER. RETURN ON AVERAGE ASSETS AND EQUITY OF 0.79% AND 11.43%, RESPECTIVELY FOR THE QUARTER ENDED MARCH 31, 2021 COMPARED TO (0.09%) AND (1.13%) FOR THE 2020 PERIOD. NEWBURGH, N.Y., April 27, 2021 (GLOBE NEWSWIRE) — ES Bancshares, Inc. (OTC: ESBS) (the “Company”) the holding company for Empire State Bank, (the “Bank”) today announced net income of $1.0 million, or $0.15 per common share for the quarter ended March 31, 2021, as compared to a net loss of $95 thousand, or $0.01 per common share for the quarter ended March 31, 2020. The increase was largely driven by a $1.3 million increase in net interest income and a $561 thousand decrease in loan loss provision compared to the 2020 period. The increase in net interest...

Continue reading

Synchronous Motor Market to Exhibit 4.33% CAGR by 2027 | Market Research Future (MRFR)

Pune, April 27, 2021 (GLOBE NEWSWIRE) — The synchronous motor market witnesses a continual growth in revenues. The market is vastly dependent on automobile sales. Therefore, the increased automotive production over the last few years has positively impacted the market growth. Besides, rising usages of these motors across the end-user industries boost the market size. The spurring rise in the oil & gas, pulp & paper, and chemical industry further substantiates market shares. Due to the exponential performance that synchronous motors offer, especially in low RPM and low-to-medium voltage applications, the market growth is expected to escalate further on the global platform. In this regard, Market Research Future (MRFR) asserts that the global synchronous motor market valuation is projected to reach approx. USD 30.09 billion...

Continue reading

BIC: FIRST QUARTER 2021 RESULTS

BIC FIRST QUARTER 2021 RESULTS1 Clichy, France, April 27th, 2021Robust results driven by the exceptional growth of U.S. Lighters in Q1, propelled by a shift in market dynamics and trading environment in both Pocket and Utility lighters Challenging underlying market trends in core Writing Instruments, worsened by the pandemic in developing countries Solid performance of Rocketbook in Digital Writing Continued growth in e-commerce, driven by all channels of trade, and share gains in key markets Improved manufacturing costs driven by procurement efficiencies Sustained Free Cash Flow and solid Net Cash Position        in million euros Q1 2020 Q1 2021Group Net Sales 357.0 411.0Change as reported (14.1)% 15.1%Change on a comparative basis (13.8)% 20.9%Change on a constant currency basis (12.9)% 25.6%EBIT Margin 6.4% 55.3%2Adjusted...

Continue reading

BIC : RÉSULTATS DU PREMIER TRIMESTRE 2021

RÉSULTATS DU PREMIER TRIMESTRE 20211 Clichy, France, le 27 avril 2021Résultats solides portés par une exceptionnelle croissance des briquets aux Etats-Unis au 1er trimestre, soutenue par un changement de la dynamique du marché dans les briquets de poche et les briquets utilitaires Tendances sous-jacentes défavorables dans les instruments d’écriture, aggravées par la pandémie dans les marchés en croissance Bonne performance de Rocketbook dans l’écriture numérique Poursuite de la croissance dans le e-commerce sur l’ensemble des réseaux de distribution et gains de parts de marché sur les marchés-clés. Amélioration des coûts de production grâce à des gains d’efficacité en matière d’approvisionnement Robuste génération de flux de trésorerie disponible et solide position nette de trésorerieEn millions d’euros T1 2020 T1 2021Chiffre...

Continue reading

Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma

STI-3031 was discovered from Sorrento’s fully human G-MAB™ library. Currently, six G-MAB antibodies are in Phase 1b through Phase 3 clinical trials in immuno-oncology and COVID-19 indications. These clinical and pre-clinical G-MAB antibodies are expected to be the foundation for developing potent antibody drug conjugates (ADCs) and antibody drug nanoparticle albumin-bound (ADNAB) product candidates. G-MAB antibodies have also been used for the generation and production of both CAR-T and DAR-T™ cells for treating hematological cancer and solid tumors.SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) — Over the last several months, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and its development partners have advanced into clinical development (Phase 1b through Phase 3 clinical trials) a number of fully human monoclonal...

Continue reading

NEURONES : Mise à disposition du Document d’Enregistrement Universel 2020

    INFORMATION PRESSE Rubrique : Document d’Enregistrement Universel 2020       Nanterre, le 27 avril 2021               Mise à disposition du Document d’Enregistrement Universel 2020         Le Document d’Enregistrement Universel 2020 a été déposé auprès de l’Autorité des Marchés Financiers (AMF) le 27 avril 2021.   Il inclut le rapport financier annuel.   Conformément à l’article 212-13 du Règlement général de l’AMF, il est tenu gratuitement à la disposition du public dans les conditions prévues par la réglementation : il est accessible dès ce jour, sous format électronique, sur le site de la société à l’adresse www.neurones.net, rubrique « Investisseurs / Informations réglementées / Rapports annuels ».                 A propos de NEURONES   Avec 5 600 personnes, et figurant parmi les leaders français du conseil en management et des...

Continue reading

Yellow Boosts Fleet, Deploys More Than 1,200 New, State-of-the-Art Peterbilt Tractors on The Road

OVERLAND PARK, Kan., April 27, 2021 (GLOBE NEWSWIRE) — Yellow Corporation (NASDAQ: YELL) is proud to announce the purchase of more than 1,200 new tractors from Peterbilt Motors Company. The new equipment, Peterbilt’s flagship Model 579 Day Cab, is coming off their Denton, Texas assembly line daily and is making its way to Yellow facilities and drivers across the country. “I’m thrilled to provide this brand-new equipment to our drivers and buy it from a great American company. We are proud to refresh and modernize much of our fleet,” said Yellow Chief Executive Officer Darren Hawkins. “This is not only a boost for our employees but it’s a win for the economy and America’s frontline workers.” In the first quarter of 2021, Yellow took delivery of more than 1,100 tractors, 1,600 trailers and 140 containers. The Company’s capital expenditures...

Continue reading

Coface records a good start to the year with a net income of €56.4m

Paris, 27 April 2021 – 17.35 Coface records a good start to the year with a net income of €56.4mTurnover: €378m, up 4.2% at constant FX and perimeterTrade credit insurance growing by 6.1% at constant FX benefiting from stabilising client activity Client retention close to record highs; positive price effect (+2.9%) Business Information continues to grow (+9% at constant FX) Factoring and debt collection down on lower volumesNet loss ratio at 24.5%, down by 32.6 ppts; combined ratio at 52.8% (61.1% excluding the effect of government schemes)Gross loss ratio at 29.5%, an improvement by 25.7 ppts; low level of claims worldwide Net cost ratio down by 1.5 ppt to 28.3%, thanks to strict cost discipline and revenue growth Government schemes have lowered pre-tax profit by €15mNet income (group share) at €56.4m, grew more than four-fold...

Continue reading

Coface enregistre un bon début d’année avec un résultat net de 56,4 M€

Paris, le 27 avril 2021 – 17h35 Coface enregistre un bon début d’année avec un résultat net de 56,4 M€Chiffre d’affaires : 378 M€, en hausse de 4,2% à périmètre et taux de change constantsL’assurance-crédit progresse de 6,1% à changes constants, bénéficiant de la stabilisation de l’activité client La rétention client reste proche des records ; l’effet prix est positif (+2,9%) Les services d’information poursuivent leur croissance (+9% à changes constants) L’affacturage et le recouvrement de créances enregistrent des volumes en baisseRatio de sinistralité net à 24,5%, en amélioration de 32,6 ppts ; ratio combiné net à 52,8% et 61,1% hors effet des schémas gouvernementauxRatio de sinistralité brut (29,5%) en amélioration de 25,7 ppts ; faiblesse des sinistres dans toutes les régions Ratio de coûts net en amélioration de 1,5 ppt...

Continue reading

Tricida to Report First Quarter Financial Results and Host Conference Call and Webcast on Thursday, May 6, 2021

SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) — Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its first quarter 2021 financial results after the close of market on Thursday, May 6, 2021. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its first quarter financial results and business progress. The call or webcast may be accessed as follows: Tricida Conference Call Information Tricida will host its First Quarter Financial Results and Business Update Conference Call and webcast on Thursday, May 6, 2021 at 4:30 pm Eastern Time. The call or webcast may be accessed as follows:Tricida Conference Call Thursday, May 6, 2021 4:30 pm Eastern Time     Webcast: Dial-In: International: Conference ID:IR.Tricida.com(877) 377-5478(629) 228-0740 9047649 A replay...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.